glp 1 for alzheimer's Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in and Parkinson's Diseases | CNS Drugs GLP-1 Drugs and Brain Health:

In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Incretin hormones are released whenever food is consumed

But we dont know exactly what that regimen would look like. About 40% of adults in the U.S

After this point, you may begin to see a gradual decline in potency, which can skew your research results

for Wegovy, administer if at least 2 days remain before the next dose